US phase III trial of nabiximols (Sativex) for spasticity due to multiple sclerosis

Trial Profile

US phase III trial of nabiximols (Sativex) for spasticity due to multiple sclerosis

Planning
Phase of Trial: Phase III

Latest Information Update: 07 May 2014

At a glance

  • Drugs Nabiximols (Primary)
  • Indications Multiple sclerosis
  • Focus Registrational; Therapeutic Use
  • Most Recent Events

    • 07 May 2014 According to the GW Pharmaceuticals media release published on 7 May 2014, the US FDA granted Special Protocol Assessment.
    • 15 Aug 2013 New trial record
    • 14 Aug 2013 GW Pharmaceuticals has opened a Phase 3 IND application with the US FDA and this trial is expected to commence in 2014, according to a media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top